Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
A global live cell barcoding approach for multiplexed mass cytometry profiling of mouse tumors
Soren Charmsaz, … , Elizabeth Jaffee, Won Jin Ho
Soren Charmsaz, … , Elizabeth Jaffee, Won Jin Ho
Published March 9, 2021
Citation Information: JCI Insight. 2021;6(7):e143283. https://doi.org/10.1172/jci.insight.143283.
View: Text | PDF
Resource and Technical Advance Immunology Oncology

A global live cell barcoding approach for multiplexed mass cytometry profiling of mouse tumors

  • Text
  • PDF
Abstract

With the advent of cancer immunology, mass cytometry has been increasingly employed to characterize the responses to cancer therapies and the tumor microenvironment (TME). One of its most notable applications is efficient multiplexing of samples into batches by dedicating a number of metal isotope channels to barcodes, enabling robust data acquisition and analysis. Barcoding is most effective when markers are present in all cells of interest. While CD45 has been shown to be a reliable marker for barcoding all immune cells in a given sample, a strategy to reliably barcode mouse cancer cells has not been demonstrated. To this end, we identified CD29 and CD98 as markers widely expressed by commonly used mouse cancer cell lines. We conjugated anti-CD29 and anti-CD98 antibodies to cadmium or indium metals and validated their utility in 10-plex barcoding of live cells. Finally, we established a potentially novel barcoding system incorporating the combination of CD29, CD98, and CD45 to multiplex 10 tumors from s.c. MC38 and KPC tumor models, while successfully recapitulating the known contrast in the PD1-PDL1 axis between the 2 models. The ability to barcode tumor cells along with immune cells empowers the interrogation of the tumor-immune interactions in mouse TME studies.

Authors

Soren Charmsaz, Nicole Gross, Elizabeth Jaffee, Won Jin Ho

×

Figure 3

Testing optimized CD29 barcoding system.

Options: View larger image (or click on image) Download as PowerPoint
Testing optimized CD29 barcoding system.
(A) Using 112Cd-, 113In-, 114Cd...
(A) Using 112Cd-, 113In-, 114Cd-, 115In-, and 116Cd-conjugated anti-CD29 and anti-CD98 antibodies, 10 unique barcodes were established for both anti-CD29 and anti-CD98 utilizing a 5-choose-3 barcoding strategy. MC38 and KPC cancer cell lines were stained using the aforementioned antibodies at a concentration of 0.25 μg/100 μL. (B) Ten-plexed MC38 and 10-plexed KPC samples were debarcoded using their respective gating hierarchies back to their original individual samples. Representative gating schema for the MC38 batch stained with anti-CD29 barcodes are shown. (C and D) Distribution of individual anti-CD29 barcodes (C) and anti-CD98 barcodes (D) yielded from the debarcoding process of MC38 and KPC samples. Both CD29 and CD98 barcoding systems resulted in a fairly even distribution of all 10 barcodes in MC38 and KPC samples.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts